Overview

A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 mg Cenobamate Administered Orally

Status:
Recruiting

Trial end date:
2022-12-17

Target enrollment:

Participant gender:

Summary

This study is a phase 1, randomized, open-label, single center, single-dose, 6-sequence, 3-period, 3-treatment crossover study in healthy adult male and female subjects to assess: the relative bioavailability of a crushed 200 mg, intact (whole) 200 mg and crushed 200 mg tablet via NG tube of cenobamate. All treatments will be administered under fasting conditions.

Phase:

Phase 1

Details

Lead Sponsor:

SK Life Science, Inc.

Treatments:

Cenobamate